Nexalin Technology (NASDAQ:NXL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Nexalin Technology (NASDAQ:NXL) to a hold rating in a research note released on Saturday morning.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Nexalin Technology in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Nexalin Technology Trading Down 2.0%

Shares of NASDAQ NXL opened at $1.47 on Friday. The company has a market cap of $25.95 million, a price-to-earnings ratio of -1.93 and a beta of 3.62. Nexalin Technology has a 12-month low of $0.70 and a 12-month high of $4.49. The stock’s 50 day simple moving average is $1.12 and its 200 day simple moving average is $1.15.

Nexalin Technology (NASDAQ:NXL) last posted its earnings results on Wednesday, August 6th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04. Nexalin Technology had a negative return on equity of 209.20% and a negative net margin of 5,057.14%.The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.04 million.

About Nexalin Technology

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.